THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity
LOS ANGELES, CA – (March 28, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of its cannabosides intellectual property (Publ. No. WO2017053574 A1) in all major pharmaceutical markets worldwide.
After initial submission through the Patent Cooperation Treaty (PCT), an international patent law treaty that provides a unified filing process for 151 countries, Vitality Biopharma has now begun submission for its patent applications in the U.S., Europe, Japan, and additional key regions. Upon patent grant, coverage of underlying patent claims would extend to at least 2035, and ensure intellectual property protection in all major pharmaceutical markets worldwide.
The filings include “composition of matter” patent claims covering Vitality’s THC prodrugs and lead drug candidate VBX-100, a gut-targeted cannabinoid pharmaceutical. VBX-100 and the Company’s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract with limited entry into the bloodstream or brain. As a result, Vitality’s prodrugs may provide targeted relief of Crohn’s disease and other digestive disorders, providing therapeutic effects without any psychoactivity.
“We are excited to initiate patent prosecution in the U.S. and global pharmaceutical markets, where we are seeking broad patent coverage for VBX-100 and the entire portfolio of cannabosides,” said Dr. Brandon Zipp, Director of R&D, and Scientific Co-founder of Vitality Biopharma. Robert Brooke, the Company’s CEO, adds that, “Today, Vitality is positioned very well for growth, as we have a highly differentiated and proprietary set of compounds that could dramatically alter the quality-of-life for patients.”
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.